# OnCo record paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002" ;
  schema:name "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer"@en ;
  schema:description "1,207 patients were randomised between four platinum doublets. All four gave the same result: about one in five responded and median survival was just under eight months. Chemotherapy had reached a ceiling."@en ;
  schema:url <https://onco.cc/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa011954>, <https://pubmed.ncbi.nlm.nih.gov/11784875/> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa011954> ;
  schema:datePublished "2002"^^xsd:gYear ;
  schema:author "Schiller JH, Harrington D, Belani CP, et al." ;
  onco:related <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/>, <https://onco.cc/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/ecog-acrin/> ;
  onco:terms <https://onco.cc/terms/performance-status/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .